Yudong joined the Allen Institute for Immunology in 2023, with 25 years of biotech/pharma experience. He has led Computational Biology teams at Rosetta Inpharmatics, Merck, Amgen, and Inflammatix, tackling a broad range of clinical and public health challenges in areas of immune-related, hepatic, and cardiovascular diseases, oncology, neuroscience, and women’s health. Yudong has authored or co-authored over 150 publications and holds more than 20 patents.

At Rosetta, Yudong pioneered novel algorithms and genomic applications, including the 70-gene breast cancer prognosis classifier that led to the EU-cleared and FDA-approved MammaPrint test. His tenure at Merck and Amgen was marked by significant contributions to multiple therapeutic programs via target discovery, liability assessment, safety issue resolution, and enablement of IND filings. He played a pivotal role in developing new platforms and data integration strategies for biomarker identification, mechanism of action elucidation, and predictive and translational safety modeling. Most recently at Inflammatix, Yudong spearheaded discovery and translational research focusing on multi-gene signatures for molecular diagnostic tests that assess host immune response.

Yudong received a PhD in Physics from the University of California at Berkeley and an MBA from the University of Washington Foster School of Business.